Filing Flows › Maze Therapeutics (MAZE) › Stock forecast & fair value
Maze Therapeutics (MAZE) stock forecast and price target
Maze Therapeutics (MAZE) trades at $34.19. 13 analysts' median price target is $55.00 (+61%), from $46.00 to $110.00.
Maze Therapeutics' latest quarter
Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%, net loss $24.2M, operating cash flow −$39.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for MAZE stock?
The median of 13 analysts' 12-month targets is $55.00, +61% from $34.19; the range is $46.00 to $110.00. The average rating is strong buy.
Does Maze Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 67% of the quarters on record.
Is MAZE stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.